Latest News
One of the biggest issues with risk when it comes to investing is that investors will invariably think about it in binary terms; what is the level of risk? Is it too high or too low? Of greater import, however, is understanding the composition of risk.
Given where the funds industry is today, as end investors’ return expectations increase they become increasingly limited in the type of risk that they can take. This has the unintended consequence of decreasing the efficiency of the overall portfolio as it becomes more and more concentrated in one type of risk.
The job of
Apex Fund Services has closed a USD40 million credit facility with global credit investment firm Highbridge Principal Strategies.
Peter Hughes (pictured), founder and chief executive officer, Apex Fund Services, says: “The completion of this investment further strengthens Apex’s ability to continue its expansion on a global scale. I am delighted that a well established investment firm recognises an opportunity in the business and has confidence investing in our brand and supporting us in our future development. This investment helps further solidify the Apex group’s position as one of the world’s leading independent fund administrator as we continue to increase our
Sunshine Heart has acquired the Aquadex product line from an indirect subsidiary of Baxter International, a specialist in the hospital products and dialysis markets.
The Aquadex system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalisation.
"Aquadex is an important strategic investment, which allows Sunshine Heart to strengthen our presence in the heart failure market," says John Erb, Sunshine's chairman and CEO. "We believe Aquadex is a
JZ Capital Partners (JZCP), a London listed fund that invests in US and European micro-cap companies and US real estate, has closed an investment in Pacific Medical, its fourth investment through the Jordan Health Products platform since 2015.
JZCP invested USD4.2 million in the transaction.
Founded in 2005 and based in San Juan Capistrano, California, Pacific Medical repairs, services and sells new and refurbished medical equipment, specialising in patient monitoring devices and corresponding accessories.
Jordan Health Products was formed in 2015 by Jordan Industries International and JZCP to develop and execute a strategic build-up in the highly fragmented
Investcorp is selling Crisps Topco Limited (Tyrrells) to Amplify Snack Brands for an enterprise value of GBP300 million.
Founded at Tyrrells Court Farm, Herefordshire in 2002, Tyrrells is a manufacturer of hand-cooked potato and vegetable crisps, popcorn and other savoury snacks.
Tyrrells has built on the brand strength of its core product offering to diversify into other premium snack categories, including popcorn, tortilla chips and vegetable crisps.
Investcorp acquired Tyrrells in August 2013 for GBP100 million and has overseen a transformation of the company in which sales and EBITDA more than doubled and employee numbers grew by over
Amadeus Capital Partners has made a growth capital investment in Igenomix, an in-vitro fertilization (IVF) genetic testing company based in Valencia, Spain.
Igenomix’s main customers are providers of fertility treatments across the world. Its genetic services encompass all phases of fertility treatment, through preconception, pre-implantation and pre-natal, providing tests that help parents to increase their chances of having a healthy baby by screening embryos for chromosome and single gene disorders.
Igenomix tested over 30,000 embryos in 2015 in its six laboratories in Valencia, Miami, Los Angeles, New Delhi, São Paulo and Dubai and has a team of over 140
Four words spring to mind when discussing the evolution of The Bahamas as a leading international financial jurisdiction: regulation, location, expertise and innovation.
Collectively, they provide a multi-layered value proposition that is helping The Bahamas cement a reputation for not only committing to a regulatory framework that embraces and, indeed, reflects international best practices, but which encourages tangible innovation. In other words, The Bahamas is a jurisdiction that gets things done, rather than just talking about it.
One only has to see the incredible success of the SMART funds series to appreciate this. First introduced in 2003, there are now
The Scottish Loan Fund (SLF) and Maven have exited their investment in Cumbernauld-based Spaceright Europe, a manufacturer and supplier of furniture, presentation products, toys and activity equipment for the education sector.
Spaceright’s range of products is used in nurseries, schools and universities throughout the UK.
Since its original investment in May 2014, SLF has provided GBP2.2 million of funding to the business, initially backing the acquisition of Educational Technology as well as supporting product development for the enlarged business. In 2015, SLF further supported Spaceright in the acquisition of Millhouse Manufacturing Design, a designer and manufacturer of a complementary
The expanded StepStone Infrastructure and Real Assets Group (SIRA) is now fully integrated into private markets asset management and advisory firm StepStone Group and is actively conducting business for the company’s clients.
In May, StepStone announced that KPMG’s infrastructure and real assets investment advisory team would join StepStone. SIRA’s more than 20 professionals, led by James O’Leary, former head of the KPMG team and Colonial First State’s infrastructure and real assets platform, operate out of Sydney, Perth, Toronto, London, La Jolla and New York.
Monte Brem, chief executive officer of StepStone, says: “We are pleased at how quickly and
The Food Revolution Group is to sell its New Zealand-based business and bioactive intellectual property and lease its LangTech Citrus (LTC) assets to Singaporean company Gravity Solutions Global (GSG), in a deal worth more than AUD17 million over 10 years.
FOD chief executive Bill Nikolovski says the deal will allow the company to focus on commercialising its range of consumer products and growing its market share in Australia and internationally.
“This will significantly reduce our expenditure on further research and development of ingredients and technologies. The sale of the bioactives and ingredient intellectual property will give us value for
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
